Novel Piflufolastat F 18 Formulation for Enhanced Prostate Cancer Imaging gets FDA Approval
The U.S. Food and Drug Administration (FDA) has recently approved a new formulation of piflufolastat F 18 (branded as Pylarify TruVu), which is utilized in positron emission tomography (PET) imaging for prostate cancer. This updated formulation aims to improve diagnostic accessibility and operational efficiency in prostate-specific membrane antigen (PSMA) PET imaging.
The new formulation of piflufolastat F 18 has been designed to enhance manufacturing outcomes, specifically by increasing batch sizes by about 50%. This manufacturing improvement is expected to augment the reliability of supply, which is crucial for maintaining continuity in the delivery of PSMA PET imaging services. Additionally, the increased radioactivity in the new formulation extends its shelf life, facilitating broader geographic distribution and allowing for more flexibility in scheduling without affecting the anticipated diagnostic performance.
Supported under the 505(b)(2) regulatory pathway, this newly approved formulation will be launched throughout the year, expanding high-quality PSMA PET imaging access across different regions while maintaining diagnostic accuracy.
Dorothy Barr, Senior Vice President of Manufacturing and Technical Operations at Lantheus, emphasized the importance of the new formulation, stating it is created to optimize manufacturing efficiency and reinforce supply chain reliability, ultimately enhancing the ability of the healthcare system to provide accurate and timely imaging for prostate cancer patients.
The previous version of piflufolastat F 18 received FDA approval in May 2021 and has been vital for detecting prostate cancer, owing to its ability to bind to PSMA, a protein overexpressed in prostate cancer cells. This binding facilitates the visualization and identification of PSMA-positive lesions during PET scans. Clinical studies, including the phase 3 CONDOR study, have confirmed the agent's positive predictive value, with successful lesion detection in 59% to 66% of cases with biochemical recurrence, even at low prostate-specific antigen (PSA) levels.
Another pivotal trial, the phase 2/3 OSPREY study, highlighted the agent's high specificity and modest sensitivity, showcasing its efficacy in accurately identifying nodal disease in high-risk patients undergoing prostatectomy and lymphadenectomy.
The development of this refined formulation is anticipated to further transform the treatment approach for recurrent or metastatic prostate cancer, allowing the focus to shift from testosterone suppression and chemotherapy to targeted radiation for early oligometastatic disease management. This paradigm shift could potentially delay the initiation of androgen deprivation therapy and chemotherapy in selected patient groups.
Safety evaluations indicate that the updated formulation maintains a consistent safety profile, with piflufolastat F 18 being generally well-tolerated by patients, who report minimal adverse effects such as headache, fatigue, and dysgeusia.